{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:19:43Z","timestamp":1791933583772,"version":"4.3.4"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004794","name":"CNRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"INSERM","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"the Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-21-CE35-0002-01"],"award-info":[{"award-number":["ANR-21-CE35-0002-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"the Fondation pour la Recherche M\u00e9dicale, \u00ab \u00c9quipe FRM \u00bb","doi-asserted-by":"publisher","award":["EQU202103012596"],"award-info":[{"award-number":["EQU202103012596"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ganaplacide, also known as KAF156, is among the new antimalarial drug candidates that have successfully reached Phase III clinical trials, and is proposed in combination with lumefantrine. This combination could replace the current front-line artemisinin-based combination therapies (ACTs) in case of Plasmodium falciparum resistance to both artemisinins and partner drugs. Indeed, the African continent, where the malaria burden is the highest, is currently experiencing worrying multiple emergences and spread of artemisinin resistance, which urges for the exploration of the antiparasitic properties of KAF156 in this context.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives and methods<\/jats:title>\n                    <jats:p>The objectives of this work were firstly to evaluate the risk of cross-resistance between artemisinins and KAF156 alone, and in combination with lumefantrine, using a panel of artemisinin-resistant strains carrying different pfk13 mutations and markers of other antiplasmodial drug resistances; secondly to explore in vitro the relevance of combining KAF156 and lumefantrine with artemisinins, based on the model of triple ACTs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our results highlighted that KAF156 activity was not impaired by mutations in pfk13, pfcrt, pfmdr1, pfmdr2, pfdhps and pfdhfr genes or by pfmdr1 amplification. Moreover, we demonstrated that KAF156 alone and in combination with lumefantrine was active against artemisinin-resistant parasites, including when they are quiescent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>All these in vitro results evidence that multi-drug resistant parasites currently in circulation in the field might not affect KAF156 efficacy, and are encouraging signs for KAF156 use in a triple ACT to preserve the use of artemisinins for as long as possible.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkae300","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:13:52Z","timestamp":1724285632000},"page":"2877-2886","source":"Crossref","is-referenced-by-count":10,"title":["<i>In vitro<\/i>\n                    evaluation of ganaplacide\/lumefantrine combination against\n                    <i>Plasmodium falciparum<\/i>\n                    in a context of artemisinin resistance"],"prefix":"10.1093","volume":"79","author":[{"given":"Jeanne","family":"Manaranche","sequence":"first","affiliation":[{"name":"LCC-CNRS, Laboratoire de Chimie de Coordination, Universit\u00e9 de Toulouse, CNRS , Toulouse ,","place":["France"]},{"name":"MAAP, New Antimalarial Molecules and Pharmacological Approaches , Inserm ERL 1289, Toulouse ,","place":["France"]},{"name":"Institut de Pharmacologie et de Biologie Structurale (IPBS), Universit\u00e9 de Toulouse, CNRS, Universit\u00e9 Toulouse III\u2014Paul Sabatier (UT3) , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Laurent","sequence":"additional","affiliation":[{"name":"LCC-CNRS, Laboratoire de Chimie de Coordination, Universit\u00e9 de Toulouse, CNRS , Toulouse ,","place":["France"]},{"name":"MAAP, New Antimalarial Molecules and Pharmacological Approaches , Inserm ERL 1289, Toulouse ,","place":["France"]},{"name":"Institut de Pharmacologie et de Biologie Structurale (IPBS), Universit\u00e9 de Toulouse, CNRS, Universit\u00e9 Toulouse III\u2014Paul Sabatier (UT3) , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxane","family":"Tressieres","sequence":"additional","affiliation":[{"name":"LCC-CNRS, Laboratoire de Chimie de Coordination, Universit\u00e9 de Toulouse, CNRS , Toulouse ,","place":["France"]},{"name":"MAAP, New Antimalarial Molecules and Pharmacological Approaches , Inserm ERL 1289, Toulouse ,","place":["France"]},{"name":"Institut de Pharmacologie et de Biologie Structurale (IPBS), Universit\u00e9 de Toulouse, CNRS, Universit\u00e9 Toulouse III\u2014Paul Sabatier (UT3) , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Nguyen","sequence":"additional","affiliation":[{"name":"LCC-CNRS, Laboratoire de Chimie de Coordination, Universit\u00e9 de Toulouse, CNRS , Toulouse ,","place":["France"]},{"name":"MAAP, New Antimalarial Molecules and Pharmacological Approaches , Inserm ERL 1289, Toulouse ,","place":["France"]},{"name":"Institut de Pharmacologie et de Biologie Structurale (IPBS), Universit\u00e9 de Toulouse, CNRS, Universit\u00e9 Toulouse III\u2014Paul Sabatier (UT3) , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Salim","sequence":"additional","affiliation":[{"name":"LCC-CNRS, Laboratoire de Chimie de Coordination, Universit\u00e9 de Toulouse, CNRS , Toulouse ,","place":["France"]},{"name":"MAAP, New Antimalarial Molecules and Pharmacological Approaches , Inserm ERL 1289, Toulouse ,","place":["France"]},{"name":"Institut de Pharmacologie et de Biologie Structurale (IPBS), Universit\u00e9 de Toulouse, CNRS, Universit\u00e9 Toulouse III\u2014Paul Sabatier (UT3) , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"Ouji","sequence":"additional","affiliation":[{"name":"LCC-CNRS, Laboratoire de Chimie de Coordination, Universit\u00e9 de Toulouse, CNRS , Toulouse ,","place":["France"]},{"name":"MAAP, New Antimalarial Molecules and Pharmacological Approaches , Inserm ERL 1289, Toulouse ,","place":["France"]},{"name":"Institut de Pharmacologie et de Biologie Structurale (IPBS), Universit\u00e9 de Toulouse, CNRS, Universit\u00e9 Toulouse III\u2014Paul Sabatier (UT3) , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Reyser","sequence":"additional","affiliation":[{"name":"LCC-CNRS, Laboratoire de Chimie de Coordination, Universit\u00e9 de Toulouse, CNRS , Toulouse ,","place":["France"]},{"name":"MAAP, New Antimalarial Molecules and Pharmacological Approaches , Inserm ERL 1289, Toulouse ,","place":["France"]},{"name":"Institut de Pharmacologie et de Biologie Structurale (IPBS), Universit\u00e9 de Toulouse, CNRS, Universit\u00e9 Toulouse III\u2014Paul Sabatier (UT3) , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinedu O","family":"Egwu","sequence":"additional","affiliation":[{"name":"LCC-CNRS, Laboratoire de Chimie de Coordination, Universit\u00e9 de Toulouse, CNRS , Toulouse ,","place":["France"]},{"name":"MAAP, New Antimalarial Molecules and Pharmacological Approaches , Inserm ERL 1289, Toulouse ,","place":["France"]},{"name":"Institut de Pharmacologie et de Biologie Structurale (IPBS), Universit\u00e9 de Toulouse, CNRS, Universit\u00e9 Toulouse III\u2014Paul Sabatier (UT3) , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Robert","sequence":"additional","affiliation":[{"name":"LCC-CNRS, Laboratoire de Chimie de Coordination, Universit\u00e9 de Toulouse, CNRS , Toulouse ,","place":["France"]},{"name":"MAAP, New Antimalarial Molecules and Pharmacological Approaches , Inserm ERL 1289, Toulouse ,","place":["France"]},{"name":"Institut de Pharmacologie et de Biologie Structurale (IPBS), Universit\u00e9 de Toulouse, CNRS, Universit\u00e9 Toulouse III\u2014Paul Sabatier (UT3) , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Augereau","sequence":"additional","affiliation":[{"name":"LCC-CNRS, Laboratoire de Chimie de Coordination, Universit\u00e9 de Toulouse, CNRS , Toulouse ,","place":["France"]},{"name":"MAAP, New Antimalarial Molecules and Pharmacological Approaches , Inserm ERL 1289, Toulouse ,","place":["France"]},{"name":"Institut de Pharmacologie et de Biologie Structurale (IPBS), Universit\u00e9 de Toulouse, CNRS, Universit\u00e9 Toulouse III\u2014Paul Sabatier (UT3) , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9468-4823","authenticated-orcid":false,"given":"Fran\u00e7oise","family":"Benoit-Vical","sequence":"additional","affiliation":[{"name":"LCC-CNRS, Laboratoire de Chimie de Coordination, Universit\u00e9 de Toulouse, CNRS , Toulouse ,","place":["France"]},{"name":"MAAP, New Antimalarial Molecules and Pharmacological Approaches , Inserm ERL 1289, Toulouse ,","place":["France"]},{"name":"Institut de Pharmacologie et de Biologie Structurale (IPBS), Universit\u00e9 de Toulouse, CNRS, Universit\u00e9 Toulouse III\u2014Paul Sabatier (UT3) , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0359-3959","authenticated-orcid":false,"given":"Lucie","family":"Paloque","sequence":"additional","affiliation":[{"name":"LCC-CNRS, Laboratoire de Chimie de Coordination, Universit\u00e9 de Toulouse, CNRS , Toulouse ,","place":["France"]},{"name":"MAAP, New Antimalarial Molecules and Pharmacological Approaches , Inserm ERL 1289, Toulouse ,","place":["France"]},{"name":"Institut de Pharmacologie et de Biologie Structurale (IPBS), Universit\u00e9 de Toulouse, CNRS, Universit\u00e9 Toulouse III\u2014Paul Sabatier (UT3) , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"key":"2024110323530321200_dkae300-B1","author":"World Health Organization"},{"key":"2024110323530321200_dkae300-B2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1021\/cb300454t","article-title":"Insights into the role of heme in the mechanism of action of antimalarials","volume":"8","author":"Combrinck","year":"2013","journal-title":"ACS Chem Biol"},{"key":"2024110323530321200_dkae300-B3","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1186\/1475-2875-8-S1-S3","article-title":"Coartem\u00ae: the journey to the clinic","volume":"8","author":"Premji","year":"2009","journal-title":"Malar J"},{"key":"2024110323530321200_dkae300-B4","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.drudis.2015.06.009","article-title":"Supporting malaria elimination with 21st century antimalarial agent drug discovery","volume":"20","author":"Diagana","year":"2015","journal-title":"Drug Discov Today"},{"key":"2024110323530321200_dkae300-B5","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1128\/AAC.02727-13","article-title":"KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission","volume":"58","author":"Kuhen","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2024110323530321200_dkae300-B6","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1038\/s41467-020-15440-4","article-title":"Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway","volume":"11","author":"LaMonte","year":"2020","journal-title":"Nat Commun"},{"key":"2024110323530321200_dkae300-B7","doi-asserted-by":"publisher","first-page":"e00696-16","DOI":"10.1128\/mBio.00696-16","article-title":"Mutations in the Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL) confer multidrug resistance","volume":"7","author":"LaMonte","year":"2016","journal-title":"mBio"},{"key":"2024110323530321200_dkae300-B8","doi-asserted-by":"publisher","first-page":"16166","DOI":"10.1038\/nmicrobiol.2016.166","article-title":"UDP-galactose and acetyl-CoA transporters as Plasmodium multidrug resistance genes","volume":"1","author":"Lim","year":"2016","journal-title":"Nat Microbiol"},{"key":"2024110323530321200_dkae300-B9","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1126\/science.1211936","article-title":"Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery","volume":"334","author":"Meister","year":"2011","journal-title":"Science"},{"key":"2024110323530321200_dkae300-B10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s12936-019-2919-3","article-title":"Low polymorphisms in pfact, pfugt and pfcarl genes in African Plasmodium falciparum isolates and absence of association with susceptibility to common anti-malarial drugs","volume":"18","author":"Foguim","year":"2019","journal-title":"Malar J"},{"key":"2024110323530321200_dkae300-B11","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.3390\/genes14122124","article-title":"Imidazolopiperazine (IPZ)-induced differential transcriptomic responses on Plasmodium falciparum wild-type and IPZ-resistant mutant parasites","volume":"14","author":"Dembele","year":"2023","journal-title":"Genes (Basel)"},{"key":"2024110323530321200_dkae300-B12","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/S1473-3099(23)00209-8","article-title":"Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial","volume":"23","author":"Ogutu","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2024110323530321200_dkae300-B13","author":"Medicine for Malaria Venture"},{"key":"2024110323530321200_dkae300-B14","doi-asserted-by":"publisher","first-page":"102193","DOI":"10.1016\/j.mib.2022.102193","article-title":"Plasmodium falciparum resistance to artemisinin-based combination therapies","volume":"69","author":"Ward","year":"2022","journal-title":"Curr Opin Microbiol"},{"key":"2024110323530321200_dkae300-B15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature12876","article-title":"A molecular marker of artemisinin-resistant Plasmodium falciparum malaria","volume":"505","author":"Ariey","year":"2014","journal-title":"Nature"},{"key":"2024110323530321200_dkae300-B16","doi-asserted-by":"publisher","first-page":"e01320-21","DOI":"10.1128\/AAC.01320-21","article-title":"Mutation in the Plasmodium falciparum BTB\/POZ domain of K13 protein confers artemisinin resistance","volume":"66","author":"Paloque","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2024110323530321200_dkae300-B17","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1086\/656476","article-title":"Artemisinin-induced dormancy in Plasmodium falciparum: duration, recovery rates, and implications in treatment failure","volume":"202","author":"Teuscher","year":"2010","journal-title":"J Infect Dis"},{"key":"2024110323530321200_dkae300-B18","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1128\/AAC.01636-09","article-title":"Increased tolerance to artemisinin in Plasmodium falciparum is mediated by a quiescence mechanism","volume":"54","author":"Witkowski","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2024110323530321200_dkae300-B19","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMoa0808859","article-title":"Artemisinin resistance in Plasmodium falciparum malaria","volume":"361","author":"Dondorp","year":"2009","journal-title":"N Engl J Med"},{"key":"2024110323530321200_dkae300-B20","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1056\/NEJMc0805011","article-title":"Evidence of artemisinin-resistant malaria in western Cambodia","volume":"359","author":"Noedl","year":"2008","journal-title":"N Engl J Med"},{"key":"2024110323530321200_dkae300-B21","doi-asserted-by":"publisher","first-page":"e51015","DOI":"10.7554\/eLife.51015","article-title":"Local emergence in Amazonia of Plasmodium falciparum k13 C580Y mutants associated with in vitro artemisinin resistance","volume":"9","author":"Mathieu","year":"2020","journal-title":"eLife"},{"key":"2024110323530321200_dkae300-B22","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","article-title":"Evidence of artemisinin-resistant malaria in Africa","volume":"385","author":"Balikagala","year":"2021","journal-title":"N Engl J Med"},{"key":"2024110323530321200_dkae300-B23","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","article-title":"Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda","volume":"26","author":"Uwimana","year":"2020","journal-title":"Nat Med"},{"key":"2024110323530321200_dkae300-B24","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa2211803","article-title":"Evolution of partial resistance to artemisinins in malaria parasites in Uganda","volume":"389","author":"Conrad","year":"2023","journal-title":"N Engl J Med"},{"key":"2024110323530321200_dkae300-B25","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/s41564-023-01461-4","article-title":"Plasmodium falciparum resistant to artemisinin and diagnostics have emerged in Ethiopia","volume":"8","author":"Fola","year":"2023","journal-title":"Nat Microbiol"},{"key":"2024110323530321200_dkae300-B26","doi-asserted-by":"publisher","first-page":"e01481-21","DOI":"10.1128\/aac.01481-21","article-title":"Assessment in vitro of the antimalarial and transmission-blocking activities of cipargamin and ganaplacide in artemisinin-resistant Plasmodium falciparum","volume":"66","author":"Yipsirimetee","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2024110323530321200_dkae300-B27","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1056\/NEJMoa1602250","article-title":"Antimalarial activity of KAF156 in falciparum and vivax malaria","volume":"375","author":"White","year":"2016","journal-title":"N Engl J Med"},{"key":"2024110323530321200_dkae300-B28","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41573-023-00772-9","article-title":"Antimalarial drug discovery: progress and approaches","volume":"22","author":"Siqueira-Neto","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"2024110323530321200_dkae300-B29","author":"World Health Organization"},{"key":"2024110323530321200_dkae300-B30","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(20)30552-3","article-title":"Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial","volume":"395","author":"Van Der Pluijm","year":"2020","journal-title":"Lancet"},{"key":"2024110323530321200_dkae300-B31","doi-asserted-by":"publisher","first-page":"4244","DOI":"10.1021\/jm300041e","article-title":"Imidazolopiperazines: lead optimization of the second-generation antimalarial agents","volume":"55","author":"Nagle","year":"2012","journal-title":"J Med Chem"},{"key":"2024110323530321200_dkae300-B32","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.4269\/ajtmh.17-0798","article-title":"Multiple phenotypic and genotypic artemisinin sensitivity evaluation of Malian Plasmodium falciparum isolates","volume":"98","author":"Niar\u00e9","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"2024110323530321200_dkae300-B33","doi-asserted-by":"publisher","first-page":"e66277","DOI":"10.7554\/eLife.66277","article-title":"Plasmodium falciparum K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness","volume":"10","author":"Stokes","year":"2021","journal-title":"eLife"},{"key":"2024110323530321200_dkae300-B34","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1126\/science.781840","article-title":"Human malaria parasites in continuous culture","volume":"193","author":"Trager","year":"1976","journal-title":"Science"},{"key":"2024110323530321200_dkae300-B35","first-page":"329","article-title":"Disposable environmental chamber for assessing the drug susceptibility of malaria parasites","volume":"44","author":"Van Huyssen","year":"1993","journal-title":"Trop Med Parasitol"},{"key":"2024110323530321200_dkae300-B36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/HP.S92198","article-title":"Frequently asked questions in hypoxia research","volume":"3","author":"Wenger","year":"2015","journal-title":"Hypoxia (Auckl)"},{"key":"2024110323530321200_dkae300-B37","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3390\/pathogens12070900","article-title":"Cultivation of asexual intraerythrocytic stages of Plasmodium falciparum","volume":"12","author":"Basco","year":"2023","journal-title":"Pathogens"},{"key":"2024110323530321200_dkae300-B38","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.pt.2018.07.003","article-title":"Is there a \u2018normal\u2019 oxygen concentration for in vitro Plasmodium cultures?","volume":"34","author":"Branco","year":"2018","journal-title":"Trends Parasitol"},{"key":"2024110323530321200_dkae300-B39","doi-asserted-by":"publisher","first-page":"883","DOI":"10.2307\/3279900","article-title":"Plasmodium falciparum in culture: use of outdated erythrocytes and description of the candle jar method","volume":"63","author":"Jensen","year":"1977","journal-title":"J Parasitol"},{"key":"2024110323530321200_dkae300-B40","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1128\/AAC.05618-11","article-title":"The F423Y mutation in the pfmdr2 gene and mutations N51I, C59R, and S108N in the pfdhfr gene are independently associated with pyrimethamine resistance in Plasmodium falciparum isolates","volume":"56","author":"Briolant","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2024110323530321200_dkae300-B41","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/bfgp\/elz008","article-title":"The genomic architecture of antimalarial drug resistance","volume":"18","author":"Cowell","year":"2019","journal-title":"Brief Funct Genomics"},{"key":"2024110323530321200_dkae300-B42","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1093\/molbev\/msab120","article-title":"Mega11: molecular evolutionary genetics analysis version 11","volume":"38","author":"Tamura","year":"2021","journal-title":"Mol Biol Evol"},{"key":"2024110323530321200_dkae300-B43","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1128\/AAC.48.5.1803-1806.2004","article-title":"Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening","volume":"48","author":"Smilkstein","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2024110323530321200_dkae300-B44","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/S1473-3099(13)70252-4","article-title":"Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies","volume":"13","author":"Witkowski","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"2024110323530321200_dkae300-B45","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.3201\/eid2110.150682","article-title":"Induction of multidrug tolerance in Plasmodium falciparum by extended artemisinin pressure","volume":"21","author":"M\u00e9nard","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"2024110323530321200_dkae300-B46","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1093\/jac\/dkaa250","article-title":"Identification of compounds active against quiescent artemisinin-resistant Plasmodium falciparum parasites via the quiescent-stage survival assay (QSA)","volume":"75","author":"Reyser","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2024110323530321200_dkae300-B47","author":"World Health Organization"},{"key":"2024110323530321200_dkae300-B48","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12936-019-2701-6","article-title":"K13-propeller gene polymorphisms in Plasmodium falciparum parasite population in malaria affected countries: a systematic review of prevalence and risk factors","volume":"18","author":"Ocan","year":"2019","journal-title":"Malar J"},{"key":"2024110323530321200_dkae300-B49","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1093\/emboj\/17.14.3807","article-title":"Allelic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria","volume":"17","author":"Triglia","year":"1998","journal-title":"EMBO J"},{"key":"2024110323530321200_dkae300-B50","doi-asserted-by":"publisher","first-page":"254","DOI":"10.4269\/ajtmh.1996.55.254","article-title":"In vitro activity of antimalarials against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon","volume":"55","author":"Ringwald","year":"1996","journal-title":"Am J Trop Med Hyg"},{"key":"2024110323530321200_dkae300-B51","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1056\/NEJM200101253440403","article-title":"A molecular marker for chloroquine-resistant falciparum malaria","volume":"344","author":"Djimd\u00e9","year":"2001","journal-title":"N Engl J Med"},{"key":"2024110323530321200_dkae300-B52","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/1475-2875-11-177","article-title":"The effects of serum lipids on the in vitro activity of lumefantrine and atovaquone against Plasmodium falciparum","volume":"11","author":"Chotivanich","year":"2012","journal-title":"Malar J"},{"key":"2024110323530321200_dkae300-B53","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/j.1365-3156.2007.01843.x","article-title":"The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa","volume":"12","author":"Sisowath","year":"2007","journal-title":"Tropical Med Int Health"},{"key":"2024110323530321200_dkae300-B54","doi-asserted-by":"publisher","first-page":"7032","DOI":"10.1128\/AAC.03494-14","article-title":"Role of pfmdr1 in in vitro Plasmodium falciparum susceptibility to chloroquine, quinine, monodesethylamodiaquine, mefloquine, lumefantrine, and dihydroartemisinin","volume":"58","author":"Wurtz","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2024110323530321200_dkae300-B55","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4269\/ajtmh.2007.77.181","article-title":"Artemisinin-based combination treatment of falciparum malaria","volume":"77","author":"Nosten","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"2024110323530321200_dkae300-B56","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41467-020-20805-w","article-title":"Artemisinin-resistant K13 mutations rewire Plasmodium falciparum\u2019s intra-erythrocytic metabolic program to enhance survival","volume":"12","author":"Mok","year":"2021","journal-title":"Nat Commun"},{"key":"2024110323530321200_dkae300-B57","doi-asserted-by":"publisher","first-page":"e02235-17","DOI":"10.1128\/AAC.02235-17","article-title":"Imidazolopiperazines kill both rings and dormant rings in wild-type and K13 artemisinin-resistant Plasmodium falciparum in vitro","volume":"62","author":"Dembele","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2024110323530321200_dkae300-B58","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1126\/science.1260867","article-title":"Drug resistance. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates","volume":"347","author":"Straimer","year":"2015","journal-title":"Science"},{"key":"2024110323530321200_dkae300-B59","doi-asserted-by":"publisher","first-page":"e1008850","DOI":"10.1371\/journal.pcbi.1008850","article-title":"Novel anti-malarial drug strategies to prevent artemisinin partner drug resistance: a model-based analysis","volume":"17","author":"Kunkel","year":"2021","journal-title":"PLoS Comput Biol"},{"key":"2024110323530321200_dkae300-B60","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1038\/s41467-023-39914-3","article-title":"Preventing antimalarial drug resistance with triple artemisinin-based combination therapies","volume":"14","author":"Nguyen","year":"2023","journal-title":"Nat Commun"},{"key":"2024110323530321200_dkae300-B61","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1038\/s41591-023-02551-w","article-title":"Modeling policy interventions for slowing the spread of artemisinin-resistant pfkelch R561H mutations in Rwanda","volume":"29","author":"Zupko","year":"2023","journal-title":"Nat Med"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/11\/2877\/60272039\/dkae300.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/11\/2877\/60272039\/dkae300.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T18:53:16Z","timestamp":1730659996000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/11\/2877\/7744399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":61,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,8,29]]},"published-print":{"date-parts":[[2024,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae300","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,8,29]]}}}